All In Biotech

Drug Trial Radar · NCT04531540

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

HT201321- Repeated Insult Patch Test With Modified Challenge

Last checked: Nov 19, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Sep 9, 2013

Primary completion

Oct 18, 2013

Study completion Oct 18, 2013

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions. The study plans to enroll about 225 female or male participants with the age 18 - 79 years. The antifungal test cream will be applied on the back between the shoulder blades of the participants and covered by a special dressing patch. This will be repeated 3 times a week for the first 3 weeks of this study applying the cream on the same area of the back. At each visit the skin will be investigated for redness, dryness and other reactions. After a rest period of two weeks the test cream will be applied on the same skin area as before and on a second new skin area nearby. After 2 and 4 days the two skin areas will again be investigated for redness, dryness and other reactions.

Conditions

  • Hypersensitivity

Interventions

  • Butenafine HCl 1% (BAY1896425)Drug

    Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled SubjectsTime frame: After 4 weeks
  2. Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Enrolled SubjectsTime frame: After 6 weeks
  3. Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Evaluable SubjectsTime frame: After 4 weeks
  4. Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Evaluable SubjectsTime frame: After 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Fairfield, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.